DD028798-C4CB-43A8-81D7-711E015E23B5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.9592641261498
- age_years
- 27
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.482
- G2M_CHECKPOINT+0.456
- MYC_TARGETS_V2+0.455
- WNT_BETA_CATENIN_SIGNALING+0.446
- E2F_TARGETS+0.434
- MITOTIC_SPINDLE+0.405
- DNA_REPAIR+0.360
- TGF_BETA_SIGNALING+0.320
- MYC_TARGETS_V1+0.309
- UNFOLDED_PROTEIN_RESPONSE+0.228
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.406
- KRAS_SIGNALING_DN-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- MYOGENESIS-0.230
- SPERMATOGENESIS-0.215
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.177
- ESTROGEN_RESPONSE_LATE-0.160
- ANGIOGENESIS-0.159
- INFLAMMATORY_RESPONSE-0.155
- INTERFERON_GAMMA_RESPONSE-0.151
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F56466DC-3C0F-48BE-8A72-CEDEAEF52F00 | — | — | 0.920 |
| 2 | A1E55AC6-A41F-454A-A3B6-8F49D2AAFEF2 | — | — | 0.908 |
| 3 | 1AF24109-5FE4-4868-ADB9-5DFDB57BCA0F | — | — | 0.904 |
| 4 | 84778027-9C8E-4364-9069-70D8B86D6916 | — | — | 0.896 |
| 5 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.896 |
| 6 | 7FB45FBA-A0DE-4A56-8D24-C6ED09998EC3 | — | — | 0.885 |
| 7 | 2CB84056-3B7C-4E12-9403-596B76CCF96B | — | — | 0.879 |
| 8 | 51708DA2-649D-4817-BB26-7FD153C65965 | — | — | 0.873 |
| 9 | 9198B2FA-637D-44B2-B6E8-24B5681737AA | — | — | 0.871 |
| 10 | 694B3BE3-104F-4D90-8733-4E99230EFAC6 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.482 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.456 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.455 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.446 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.434 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.405 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.309 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.228 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.108 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.084 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.079 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.057 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.057 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.054 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.045 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.041 | Inavolisib | — uncovered |
| PEROXISOME | 0.039 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.029 | Inavolisib | — uncovered |